Hyperosmolar Hyperglycemic State: Severe Hyperglycemia, Osmotic Diuresis, and Dehydration

Core Idea

HHS occurs primarily in type 2 diabetes with massive hyperglycemia (>600 mg/dL) but preserved enough insulin to suppress ketogenesis. Severe hyperglycemic osmotic diuresis causes profound dehydration and hyperosmolality; mental status changes and thrombotic complications are common, often fatal if untreated.

Explainer

To understand the hyperosmolar hyperglycemic state (HHS), start with what differentiates it from diabetic ketoacidosis — a contrast that reveals the role of residual insulin. In type 1 diabetes, insulin is absent entirely. Without insulin, glucagon-driven lipolysis proceeds unchecked, producing ketoacids that define DKA. In type 2 diabetes, patients retain enough endogenous insulin to suppress lipolysis and ketogenesis. Glucose still rises dramatically — because that residual insulin is insufficient to permit glucose uptake into most cells — but ketones do not accumulate. HHS is hyperglycemia without acidosis, which paradoxically makes it more dangerous in some ways: the absence of acidosis removes the dramatic early warning signs (Kussmaul breathing, fruity breath) that prompt early medical attention in DKA.

The central pathophysiology is osmotic diuresis driven to an extreme. From your study of fluid balance and electrolytes, you know that glucose above the renal threshold (~180 mg/dL) spills into urine. Glucose in the tubular fluid acts as an osmotic agent, obligating water and electrolytes (sodium, potassium, magnesium, phosphate) to follow. In HHS, glucose may rise to 600–1,200 mg/dL, driving a massive, sustained osmotic diuresis. Patients may lose 8–10 liters of fluid and proportional electrolytes over hours to days. Elderly patients or those with impaired thirst sensation or limited access to water cannot compensate. The result is hyperosmolality — a serum osmolality that can exceed 350 mOsm/kg (normal ~285), meaning the extracellular fluid becomes dramatically concentrated.

Hyperosmolality has direct neurological consequences. Water follows its osmotic gradient from neurons into the hypertonic extracellular fluid, causing brain cells to shrink. This manifests as a spectrum of neurological changes — from confusion and lethargy to seizures to frank coma — that are directly proportional to the degree of hyperosmolality. Thrombosis is an equally serious complication: dehydration concentrates platelets, clotting factors, and red blood cells, dramatically increasing blood viscosity. Strokes, deep vein thromboses, and mesenteric infarctions are all recognized complications of the hypercoagulable, hemoconcentrated state of HHS.

A dangerous vicious cycle amplifies the initial insult: dehydration reduces renal blood flow, impairing the kidney's ability to clear glucose, which pushes glucose higher, which drives more osmotic diuresis. Treatment requires interrupting this cycle with careful fluid resuscitation (typically 0.9% or 0.45% saline) titrated over 24–48 hours — not too fast, because rapidly restoring osmolality can cause cerebral edema as water rushes back into previously contracted neurons. Insulin is given, but at lower doses than in DKA, because the goal is glucose reduction without precipitating the hypophosphatemia and hypokalemia that occur as anabolic metabolism resumes. The monitoring focus is on serum osmolality trending down and mental status improving — the clearest signals that the pathophysiology is reversing.